Skip to content

Contact +44 (0) 20 7060 7474 email us

Shire

Shire plc: PharmaVitae Profile

 

Publication Date November 2008
Publisher Datamonitor
Product Type Report
Pages 158
ISBN Number not applicable
Product Code DAT01633

Price

£1,990.00
approximately: $3,013 | €2,221

pdf

Buy Now

print £3,060 ($4,633 | €3,415)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

This analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 16 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Shire's performance against key rivals in the ethical pharmaceutical sector
  • Assess the impact of generic competition to Shire's blockbuster ADHD drug, Adderall XR, over 200713
  • Analyze the impact of recent acquisitions (TKT, New River Pharmaceuticals, Jerini) on Shire's financial and sales performance over 200113

Contents

  • Chapter 1 About This Profile
  • Executive Summary
    • Quarterly News Update
    • Company Introduction
    • Company Sales
    • Company Financials
    • Key Products And Competitors
    • Data Sourcing
    • Sales Data
    • Analyst Consensus
  • Chapter 2 Executive Summary
  • Key Findings
    • Prescription Pharmaceutical Sales Performance, 200113
    • Financial Performance, 200113
    • Shire: Pharmavitae Forecasts At A Glance
    • Strategic Insight
    • 1) 200104: Adhd Franchise Growth
    • Shire Becomes Adhd MarketLeader Driven By Adderall Xr Growth
    • 2) 200408: Corporate Restructuring
    • 3) 200813: Returns From M&A
    • Rx Revenue Growth To 2013 Will Be Determined By Shire's Acquired Portfolios
    • Swot Analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 3 Quarterly News Update
    • Product Developments
    • Deals And Alliances
    • Product Deals
    • Technology Deals
    • M&A Activity
    • Company Announcements
    • Future Product Milestones
  • Chapter 4 Company Introduction
  • Key Findings
    • Background
    • Key Corporate Developments
    • M&A History
    • Acquisition Of Imperial Pharmaceutical Services
    • Acquisition Of Phamavene
    • Acquisition Of Richwood
    • Merger With Roberts Pharmaceutical Corporation
    • Acquisition Of Fuisz Technologies' Eu Susidiaries
    • Acquisition Of Biochem Pharma
    • Acquisition Of Atlantic Pharmaceutical
    • Divestment Of Otc Products
    • Divestment Of Vaccines Business
    • Acquisition Of Transkaryotic Therapies
    • Acquisition Of New River Pharmaceuticals
    • Divestment Of NonCore Products
    • Acquisition Of Jerini
    • Current Corporate Structure
    • Human Genetic Therapies
  • Chapter 5 Company Sales
  • Key Findings
    • Prescription Pharmaceutical Sales And Growth Rate Analysis, 200113
    • Product Analysis
    • Product Analysis, 200107
    • Product Analysis, 200713
    • Therapy Area Analysis
    • Therapy Area Analysis, 200107
    • Therapy Area Analysis, 200713
    • Therapy Area Focus, 200113
    • Geographic Analysis
    • Geographic Analysis, 200107
    • Geographic Analysis, 200713
    • Geographic Focus, 200113
    • Launch/Core/Expiry Analysis
    • Explanation Of Launch/Core/Expiry Analysis
    • Launch Analysis, 200713
    • Core Analysis, 200713
    • Expiry Analysis, 200713
    • Launch/Core/Expiry Configuration, 200713
    • Molecule Type Analysis
    • Molecule Type Analysis, 200107
    • Molecule Type Analysis, 200713
    • Externalization Analysis
    • Externalization Analysis, 200107
    • Externalization Analysis, 200713
  • Chapter 6 Company Financials
  • Key Findings
    • Reconciliation Between PharmavitaeFormatted Prescription Pharma Sales And CompanyReported Total Sales, 200107
    • Financial Statements, 200107
    • Profit And Loss Account, 200107
    • Balance Sheet, 200107
    • Operating Costs And Profit Analysis
    • Operating Costs And Profit Analysis, 200107
    • Operating Cost Ratio And Profit Margin Analysis, 200107
    • Operating Cost Ratio And Profit Margin Analysis, 200713
    • Operating Costs And Profit Analysis, 200713
    • Return On Capital Employed Analysis
    • Capital Employed Analysis, 200107
    • Return On Capital Employed (Roce) Analysis, 200107
  • Chapter 7 Key Products And Competitors
  • Key Findings
  • Overview
    • Central Nervous System
    • Vyvanse
  • Overview
    • Sales Forecast
    • Daytrana
  • Overview
    • Sales Forecast
    • Adderall Xr
  • Overview
    • Sales Forecast
    • Intuniv
  • Overview
    • Sales Forecast
    • Adderall
  • Overview
    • Sales Forecast
    • Endocrine, Metabolic And Genetic Disorders
    • Elaprase
  • Overview
    • Sales Forecast
    • Replagal
    • Sales Forecast
    • GaGcb
    • Shire Is Developing A Human Recombinant Glucocerebrosidase Enzyme Replacement Therapy, Velaglucerase Alfa (GaGcb), For The Potential Treatment Of Type I Gaucher Disease. A Second Phase Iii Trial Was Initiated In January 2008 And Completed Enrollment The Following July. Shire Has Stated Its Intention To Make Global Filings In The Second Half Of 2009, With Launch In Both The Eu And The Us In 2010
  • Overview
    • Sales Forecast
    • Gastroenterology
    • Lialda
    • Shire Launched Lialda, A Multimatrix (Mmx), SustainedRelease Formulation Of Mesalazine, In The Us Market In March 2007. It Is Indicated For The Treatment Of MildToModerate Ulcerative Colitis, And Is A FollowOn Formulation Of Shire's Existing Gastroenterology Offering, Pentasa. It Also Reached The German And Irish Markets In 2008, And Has Launched In The Uk Under The Brand Name Mezavant
    • Having Achieved Strong Initial Uptake, Garnering $51m In Its First (NonComplete) Year, Lialda Is Forecast Strong Sales Growth Over 200713, At +$502m. Growth Will Be Driven By The Continued Roll Out In Further Eu And Row Markets
  • Overview
    • Sales Forecast
    • Pentasa
  • Overview
    • Sales Forecast
    • Urology And Gender Specific Health
    • Fosrenol
  • Overview
    • Sales Forecast
    • Immunology And Inflammation
    • Firazyr
  • Overview
    • Sales Forecast
  • Chapter 8 Appendix
    • R&D Pipeline
    • References
    • Abbreviations
  • List Of Tables
    • Table 1: Shire Pharmavitae Forecasts At A Glance
    • Table 2: Shire Key Product Developments, 2008
    • Table 3: Shire Product Deals And Alliances, 2008
    • Table 4: Shire Technology Deals And Alliances, 2008
    • Table 5: Shire M&A Activity, 2008
    • Table 6: Shire Company Announcements, 2008
    • Table 7: Shire Future Product Milestones, 200810
    • Table 8: Shire Product Portfolio Overview ($M), 200107
    • Table 9: Shire Product Portfolio Overview ($M), 200713
    • Table 10: Shire Product Portfolio Overview ($M), 200107
    • Table 11: Shire Product Portfolio Overview ($M), 200713
    • Table 12: Shire Portfolio Overview By Geographic Region ($M), 200107
    • Table 13: Shire Portfolio Overview By Geographic Region ($M), 200713
    • Table 14: Shire Launch Portfolio Overview ($M), 200713
    • Table 15: Shire Core Portfolio Overview ($M), 200713
    • Table 16: Shire Expiry Portfolio Overview ($M), 200713
    • Table 17: Shire Portfolio Overview By Molecule Type ($M), 200107
    • Table 18: Shire Product Portfolio Overview By Molecule Type ($M), 200713
    • Table 19: Shire Product Portfolio Overview By Source ($M), 200107
    • Table 20: Shire Product Portfolio Overview By Source ($M), 200713
    • Table 21: Total Shire Sales By Business Unit ($M), 200107
    • Table 22: Shire Profit And Loss Account ($M), 200107
    • Table 23: Shire Balance Sheet ($M), 200107
    • Table 24: Shire Operating Revenue/Cost Analysis ($M), 200107
    • Table 25: Shire Operating Cost Ratio Analysis (Percentage Of Total Revenues), 200107
    • Table 26: Shire Operating Cost Ratio Analysis (Percentage Of Total Revenues), 200713
    • Table 27: Shire Operating Revenue/Cost Analysis ($M), 200713
    • Table 28: Shire Capital Employed ($M), 200107
    • Table 29: Shire Ebit Return On Capital Employed ($M), 200107
    • Table 30: Shire Ebit PreTax Return/Ce Driver Analysis (%), 200107
    • Table 31: Key Products Overview
    • Table 32: Vyvanse: Overview
    • Table 33: Vyvanse: Sales Forecast ($M), 200713
    • Table 34: Daytrana: Overview
    • Table 35: Daytrana: Sales Forecast ($M), 200713
    • Table 36: Adderall Xr: Overview
    • Table 37: Adderall Xr: Sales Forecast ($M), 200713
    • Table 38: Intuniv: Overview
    • Table 39: Intuniv: Sales Forecast ($M), 200713
    • Table 40: Adderall: Overview
    • Table 41: Adderall: Sales Forecast ($M), 200713
    • Table 42: Elaprase: Overview
    • Table 43: Elaprase: Sales Forecast ($M), 200713
    • Table 44: Replagal: Overview
    • Table 45: Replagal: Sales Forecast ($M), 200713
    • Table 46: GaGcb: Overview
    • Table 47: GaGcb: Sales Forecast ($M), 200713
    • Table 48: Lialda: Overview
    • Table 49: Lialda: Sales Forecast ($M), 200713
    • Table 50: Pentasa: Overview
    • Table 51: Pentasa: Sales Forecast ($M), 200713
    • Table 52: Fosrenol: Overview
    • Table 53: Fosrenol: Sales Forecast ($M), 200713
    • Table 54: Firazyr: Overview
    • Table 55: Firazyr: Sales Forecast ($M), 200713
    • Table 56: Shire's R&D Pipeline (Phase IRegistration)
  • List Of Figures
    • Figure 1: Shire Prescription Pharmaceutical Performance, Sales ($M) And Growth Rate (%), 200113
    • Figure 2: Shire's Financial Performance ($M), 200113
    • Figure 3: Shire Rx Revenue And Financial Performance ($M), 200113
    • Figure 4: Shire Adhd Franchise Revenue ($M), 200113
    • Figure 5: Shire Rx Revenue ($M) By Source, 200113
    • Figure 6: Shire Swot Analysis
    • Figure 7: M&A/Divestment History
    • Figure 8: Current Corporate Structure
    • Figure 9: Shire Prescription Pharmaceutical Performance, Sales ($M) And Growth Rate (%), 200113
    • Figure 10: Shire Key Sales Growth Driver & Resistors ($M), 200107
    • Figure 11: Shire Key Sales Growth Drivers & Resistors ($M), 200713
    • Figure 12: Shire Prescription Pharmaceutical Sales By Therapy Area ($M), 200113
    • Figure 13: Shire Prescription Pharma Sales By Therapy Area (% Of Total), 200113
    • Figure 14: Shire Prescription Pharmaceutical Sales By Geographic Region ($M), 200113
    • Figure 15: Shire Growth Drivers And Resistors By Geographic Region ($M), 200107
    • Figure 16: Shire Drivers And Resistors By Geographic Region ($M), 200713
    • Figure 17: Shire Prescription Pharmaceutical Sales By Geographic Region (% Of Total), 200113
    • Figure 18: Shire Launch/Core/Expiry Configuration ($M), 200713
    • Figure 19: Shire Prescription Pharmaceutical Sales By Molecule Type ($M), 200113
    • Figure 20: Shire Growth Drivers And Resistors By Molecule Type ($M), 200713
    • Figure 21: Shire Prescription Pharmaceutical Sales By Source ($M), 200113
    • Figure 22: Shire Growth Drivers And Resistors By Source ($M), 200107
    • Figure 23: Shire Growth Drivers And Resistors By Source ($M), 200713
    • Figure 24: Shire Rx Revenue By Source, 200113
    • Figure 25: Shire Operating Revenue/Cost Analysis ($M), 200113
    • Figure 26: Shire Operating Cost Ratio Analysis (Percentage Of Total Revenues), 200113
    • Figure 27: Shire Return On Capital Employed, Ebit Margin And Capital Turnover, 200107
    • Figure 28: Return On Ce Formula